The goal of this activity is for learners to be better able to apply biomarker testing for patients with ER-positive/HER2-negative MBC progressing on an AI +/ CDK4/6 inhibitors to inform treatment decisions.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 0.25 credits
MOC types
No MOC
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Pricing
100% of listed courses are free
300 of a sample of 300 are free · 1,268 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Breast Imaging
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Clinical Informatics
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Facial Plastic & Reconstructive Surgery
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Nuclear Medicine
- Obstetric Anesthesia
- Obstetrics & Gynecology
- Ophthalmology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Gastroenterology
- Pediatric Neurology
- Plastic & Reconstructive Surgery
- Preventive Medicine
- Primary Care Sports Medicine
- Pulmonary Disease
- Rheumatology
- Rhinology
- Sleep Medicine
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Blended / Other
- Credit · Up to 0.25 credits
- Commercial Support
-
ReleasedNov 11, 2025
-
Last day to claim creditNov 12, 2026 4 weeks left
-
Medscape, LLC Patients Progressing on an AI +/- CDK 4/6 Inhibitors: From Biomarkers to Treatment Strategies
-
Medscape, LLC Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data
-
Medscape, LLC ER-Positive/HER2-Negative Metastatic Breast Cancer: Nursing and Advanced Practice Perspectives
-
Kaplan Medical Education Can We Do Better? Choosing an Adjuvant CDK4/6 Inhibitor for HR+/HER2- Early Breast Cancer
-
Medical Learning Institute, Inc. Oncologist Voices from the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer
-
PRIME Education, Inc. (PRIME®) A Proactive Approach to Managing Adverse Events Associated With CDK4/6 Inhibitors
